<div id="readability-page-1"><ul><li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li></ul><p>Novo Nordisk A/S, Eli Lilly and Company, Pfizer, Bristol Myers Squibb, AbbVie, Abbott Laboratories,  and Gilead Sciences are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and sell prescription drugs and related therapies, offering investors exposure to the pharmaceutical industry's revenue and profit potential. Their value is driven by factors like clinical trial results, regulatory approvals, patent protection, and drug pricing, so they can offer substantial upside but also significant volatility and regulatory risk. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.</p><div><p><span></span><span>Get <strong>Novo Nordisk A/S</strong> alerts:</span></p></div><h2>Novo Nordisk A/S (NVO)</h2><p>Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.</p><ul><li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li></ul><p>Read Our Latest Research Report on NVO</p><h2>Eli Lilly and Company (LLY)</h2><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><ul><li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li></ul><p>Read Our Latest Research Report on LLY</p><h2>Pfizer (PFE)</h2><p>Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p><p>Read Our Latest Research Report on PFE</p><h2>Bristol Myers Squibb (BMY)</h2><p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p><p>Read Our Latest Research Report on BMY</p><h2>AbbVie (ABBV)</h2><p>AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p><p>Read Our Latest Research Report on ABBV</p><h2>Abbott Laboratories (ABT)</h2><p>Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.</p><p>Read Our Latest Research Report on ABT</p><h2>Gilead Sciences (GILD)</h2><p>Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.</p><p>Read Our Latest Research Report on GILD</p><h2>Further Reading</h2><ul><li>MarketBeat's Top Five Stocks to Own in December 2025</li><li>Micron Just Changed the AI Cycle—and the Market Knows It</li><li>Waste Management’s Next Chapter Is Taking Shape for Investors</li><li>3 Emerging Market Stocks to Buy and Hold for 2026</li><li>4 Memorable Ways to Play the HBM Market Boom</li><li>Salesforce Just Triggered a Powerful Buy Signal for 2026</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Novo Nordisk A/S Right Now?</h2><p>Before you consider Novo Nordisk A/S, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.</p><p>While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABBV

<p>MarketBeat highlights seven pharmaceutical stocks to watch: Novo Nordisk, Eli Lilly, Pfizer, Bristol Myers Squibb, AbbVie, Abbott Laboratories, and Gilead Sciences. These companies are noted for their high trading volumes and potential for substantial returns, driven by factors like clinical trial results and regulatory approvals. However, they also carry risks such as volatility and regulatory challenges. The report provides insights into each company's focus areas and recent developments.</p>

Top Pharmaceutical Stocks To Add to Your Watchlist - December 23rd